<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>AIM: To evaluate the ameliorative effect of <z:chebi fb="0" ids="50202">naringenin</z:chebi> (NG) during <z:hpo ids='HP_0100279'>ulcerative colitis</z:hpo> (UC) in rats </plain></SENT>
<SENT sid="1" pm="."><plain>METHODS: Rats were treated with three different doses (25, 50 and 100 mg/kg per day) of NG and a single dose of <z:chebi fb="0" ids="6775">mesalazine</z:chebi> (<z:chebi fb="28" ids="39005,39010">MES</z:chebi>, 300 mg/kg per day) for seven days prior to <z:hpo ids='HP_0100279'>ulcerative colitis</z:hpo> induction by 4% <z:chebi fb="22" ids="15366">acetic acid</z:chebi> (AA) </plain></SENT>
<SENT sid="2" pm="."><plain>Twenty four hours after AA rectal administration, animals were scarified and the colonic tissues were dissected </plain></SENT>
<SENT sid="3" pm="."><plain>Colonic mucus content was estimated using Alcian blue dye binding technique </plain></SENT>
<SENT sid="4" pm="."><plain>In colon tissues, levels of total <z:chebi fb="0" ids="16856">glutathione</z:chebi> sulphadryls (T-GSH), non-protein sulphadryls (NP-SH) and <z:chebi fb="0" ids="33202">thiobarbituric acid</z:chebi> reactive substances (TBARS) were evaluated </plain></SENT>
<SENT sid="5" pm="."><plain>The activities of the <z:chebi fb="11" ids="22586">antioxidant</z:chebi> enzymes, catalase (CAT) and <z:chebi fb="1" ids="18421">superoxide</z:chebi> dismutase (SOD) were measured </plain></SENT>
<SENT sid="6" pm="."><plain>Concentrations of nucleic acids (DNA and <z:chebi fb="40" ids="33697">RNA</z:chebi>) and total protein were also estimated in colon tissues </plain></SENT>
<SENT sid="7" pm="."><plain>Colonic levels of <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> <z:mp ids='MP_0001651'>necrosis</z:mp> factor-α (TNF-α), interleukin-1β (IL-1β), interleukin-6 (IL-6), <z:chebi fb="0" ids="15551">prostaglandin E2</z:chebi> (<z:chebi fb="0" ids="15551">PGE2</z:chebi>) and nitric <z:chebi fb="177" ids="25741,29356">oxide</z:chebi> (NO) were estimated </plain></SENT>
<SENT sid="8" pm="."><plain>In cross section of <z:hpo ids='HP_0002583'>colitis</z:hpo> tissue the histopathological changes were observed </plain></SENT>
<SENT sid="9" pm="."><plain>RESULTS: Colonic mucus content was decreased in AA compared to controls (587.09 ± 65.59 mg/kg vs 941.78 ± 68.41 mg/kg, P &lt; 0.001) </plain></SENT>
<SENT sid="10" pm="."><plain>AA administration markedly reduced T-GSH (5.25 ± 0.37 nmol/L vs 3.04 ± 0.24 nmol/L, P &lt; 0.01), NP-SH (3.16 ± 0.04 nmol/L vs 2.16 ± 0.30 nmol/L, P &lt; 0.01), CAT (6.77 ± 0.40 U/mg vs 3.04 ± 0.2 U/mg, P &lt; 0.01) and SOD (3.10 ± 0.11 U/mg vs 1.77 ± 0.18 U/mg, P &lt; 0.01) while TBARS, TNF-α, IL-1β, IL-6, <z:chebi fb="0" ids="15551">PGE2</z:chebi> and NO levels (15.09 ± 3.84 nmol/L vs 59.90 ± 16.34 nmol/L, P &lt; 0.01; 113.56 ± 1.91 pg/mg vs 134.24 ± 4.77 pg/mg, P &lt; 0.01; 209.20 ± 36.38 pg/mg vs 422.19 ± 31.47 pg/mg, P &lt; 0.01; 250.83 ± 25.09 pg/mg vs 638.58 ± 115.9 pg/mg, P &lt; 0.01; 248.19 ± 36.98 pg/mg vs 541.74 ± 58.34 pg/mg, P &lt; 0.01 and 81.26 ± 2.98 mmol/g vs 101.90 ± 10.73 mmol/g, P &lt; 0.001) were increased in colon of rats with UC compared controls respectively.<z:chebi fb="0" ids="50202">Naringenin</z:chebi> supplementation, significantly and dose dependently increased the colonic mucus content </plain></SENT>
<SENT sid="11" pm="."><plain>The elevated TBARS levels were significantly decreased (39.35 ± 5.86 nmol/L, P &lt; 0.05; 26.74 ± 3.17 nmol/L, P &lt; 0.01 nmol/L and 17.74 ± 2.69 nmol/L, P &lt; 0.01) compared to AA (59.90 ± 16.34 nmol/L) group while the decreased levels of T-GSH and NP-SH and activities of CAT and SOD found increased by NG treatments in dose dependent manner </plain></SENT>
<SENT sid="12" pm="."><plain>The decreased values of nucleic acids and total protein in AA group were also significantly (P &lt; 0.01) increased in <z:hpo ids='HP_0000001'>all</z:hpo> three NG supplemented groups respectively </plain></SENT>
<SENT sid="13" pm="."><plain>NG pretreatment inhibited the TNF-α levels (123.76 ± 3.76 pg/mg, 122.62 ± 3.41 pg/mg and 121.51 ± 2.61 pg/mg vs 134.24 ± 4.78 pg/mg, P &lt; 0.05) compared to AA group, respectively </plain></SENT>
<SENT sid="14" pm="."><plain>Interleukins, IL-1β and IL-6 levels were also decreased in NG50 + AA (314.37 ± 16.31 pg/mg and 292.58 ± 23.68 pg/mg, P &lt; 0.05) and NG100 + AA (416.72 ± 49.62 pg/mg and 407.96 ± 43.87 pg/mg, P &lt; 0.05) when compared to AA (352.46 ± 8.58 pg/mg and 638.58 ± 115.98 pg/mg) group </plain></SENT>
<SENT sid="15" pm="."><plain>Similar decrease (P &lt; 0.05) was seen in <z:chebi fb="0" ids="15551">PGE2</z:chebi> and NO values when compared to AA group </plain></SENT>
<SENT sid="16" pm="."><plain>The group pretreated with <z:chebi fb="28" ids="39005,39010">MES</z:chebi>, as a reference drug, showed significant (P &lt; 0.01) protection against the changes induced in colon tissue by AA administration respectively </plain></SENT>
<SENT sid="17" pm="."><plain>CONCLUSION: In present study, NG produced <z:chebi fb="11" ids="22586">antioxidant</z:chebi> and anti-inflammatory effects demonstrating protective effect in <z:e sem="disease" ids="C0021390" disease_type="Disease or Syndrome" abbrv="">inflammatory bowel disease</z:e> </plain></SENT>
</text></document>